The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms. Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.
Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.
Given this information, TOPEC Global is pleased to present this module titled “Treatment Options for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck.” This module reviews therapeutic approaches in locally-advanced SCCHN, induction strategies in managing SCCHN, the place of biomarkers and their prognostic significance, and the management of HPV-related SCCHN.